Stand Up To Cancer works relentlessly to offer the newest, most effective, and most promising cancer treatments to patients quickly by bringing together the best minds to collaborate, innovate, and share cancer research.
Stand Up To Cancer enables scientific breakthroughs by funding collaborative, multidisciplinary, multi-institutional scientific cancer research teams and investigators. Thanks to the support of our dedicated partners and the entertainment community, SU2C is able to bring widespread attention to cancer research and treatments.
Research is changing the way cancer is being treated. If you’ve been diagnosed with cancer, a clinical trial may offer access to the latest and most promising science, while helping to light the path for future survivors.
Stand Up To Cancer was created to accelerate groundbreaking cancer research that will get promising new cancer treatments to patients quickly. We won’t stop until every cancer patient is a long-term cancer survivor.
A Phase 1, Dose-Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)